PDUFA Negotiations: FDA Wants To Be Able To Call "Time-Out" During Reviews
Executive Summary
FDA has proposed a new application review model that would allow it to call a time-out, which could be used to resolve mid-cycle issues and, the agency argues, potentially bring more predictability to the process.
You may also be interested in...
Buying Time: Industry Sacrifices Early To Gain Later With PDUFA V Review Model
NMEs and novel biologics will see reviews allotted two additional months under the revised model launching Oct. 1. Industry expects to gain more communication and first-cycle approvals, while FDA hopes it can receive more complete applications at submission and improve transparency.
FDA Wants To Lengthen Review Time For Some Prior Approval Supplements
FDA wants to lengthen the goal for action on prior-approval manufacturing supplements as part of the PDUFA V reauthorization, but industry does not appear too willing to budge.
FDA Wants To Lengthen Review Time For Some Prior Approval Supplements
FDA wants to lengthen the goal for action on prior-approval manufacturing supplements as part of the PDUFA V reauthorization, but industry does not appear too willing to budge.